Document is current
Any future updates will be listed below
-
Authors
Lin, Hung-Sheng
Sung, Pei-Hsun
Huang, Shu-Hua
Lin, Wei-Che
Chiang, John Y.
Ma, Ming-Chun
Chen, Yi-Ling
Chen, Kuan-Hung
Lee, Fan-Yen
Ko, Sheung-Fat
Yip, Hon-Kan https://orcid.org/0000-0002-6305-5717
-
Clinical Trials BETA
Clinical trials referenced in this document:
isrctn15677760 at ISRCTN.orgDocuments that mention this clinical trial
Long term outcomes of intracarotid arterial transfusion of circulatory-derived autologous CD34 + cells for acute ischemic stroke patients—A randomized, open-label, controlled phase II clinical trial
https://doi.org/10.1186/s13287-024-04021-7
-
Funding
Funding for this research was provided by:
Ministry of Science and Technology of the Republic of China (MOST 107-2314-B-182A-056-MY3)
- License Information
-
More Information
Article History
Received: 24 May 2024
Accepted: 28 October 2024
First Online: 20 November 2024
Declarations
:
: This clinical trial protocol was reviewed and approved by the Taiwan Food and Drug Administration (Approval number: 1109012692) and the Institutional Review Board of Chang Gung Medical Foundation (Approval number: 201700116A0C502). This project entitled “An investigation of the therapeutic impact of intra-carotid arterial transfusion of autologous peripheral blood-derived stem cell/progenitor cell (CD34 +) therapy on brain ischemic stroke—a phase II clinical trial” was approved on July 17, 2017. Furthermore, all patients signed the approved informed consent form, and all the procedures were performed in accordance with the principles of the Declaration of Helsinki. Trial registration: ISRCTN, ISRCTN15677760. Registered 23 April 2018- Retrospectively registered, .
: Not applicable.
: The authors declare that they have no competing interests.
